Editorial Comment on “Efficacy of pembrolizumab plus lenvatinib as first‐line treatment for metastatic renal cell carcinoma with multiple brain metastases”
2024
Commentary on Efficacy of Pembrolizumab and Lenvatinib for Brain Metastases
Editorial
Author Information
Author(s): Manabu Kato
Primary Institution: Department of Urology Aichi Cancer Center Hospital
Conclusion
Multimodal treatments combining stereotactic radiation and immunotherapy plus TKI could improve overall survival for patients with renal cell carcinoma and multiple brain metastases.
Supporting Evidence
- Monotherapies with TKI or immune checkpoint inhibitors have shown efficacy in improving survival outcomes for brain metastases from RCC.
- A significant difference in overall survival was observed between patients receiving IO-based combination therapy and those receiving TKI monotherapy.
- Patients treated with stereotactic radiation for multiple BMs showed longer overall survival compared to those treated with whole brain radiation.
Takeaway
Doctors are finding that using a mix of treatments can help people with kidney cancer that has spread to the brain live longer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website